Literature DB >> 3338970

Growth of MTW9/PL2 estrogen-responsive rat mammary tumor cells in hormonally defined serum-free media.

D Danielpour1, T L Riss, M Ogasawara, D A Sirbasku.   

Abstract

Growth of the estrogen-responsive MTW9/PL2 rat mammary tumor cells was demonstrated in serum-free defined medium (designated DDM-1) formulated with F12-DME (1:1 vol/vol) supplemented with 15 mM HEPES pH 7.4, insulin 10 micrograms/ml, transferrin 10 micrograms/ml, sodium selenite 10 ng/ml, triiodo-L-thyronine 0.3 nM, phosphoethanolamine 5 microM, epidermal growth factor (20 ng/ml), 17 beta-estradiol 2 nM, and bovine serum albumin 20 micrograms/ml. In DDM-1, the growth rate was about one-half that seen in serum-containing medium. When ethanolamine (50 microM), glutathione (20 micrograms/ml), and linoleic acid/bovine serum albumin (150 micrograms/ml) were added (formulation DDM-2), the growth rate was 80% of serum-containing medium and not seed-density dependent. Deletion of estradiol from DDM-1 or DDM-2 had no effect on growth rate. Also, cells grown in steroid hormone deficient medium for 4 mo. continued to form estrogen-responsive tumors in rats as did cells cultured for the same period in 2 nM estradiol. To investigate autocrine growth factor secretion, a third medium (DDM-3) was prepared by deleting insulin, epidermal growth factor, phosphoethanolamine, estradiol, and both forms of bovine serum albumin from DDM-2. Growth in mitogen-free medium equaled 86% of the serum-stimulated rate and was seed-density dependent; phenol red deletion from DDM-3 had no effect on growth rate. Evidence presented suggests that autocrine factors stimulate growth of the MTW9/PL2 cells in DDM-3, and that this secretion may support the growth of estrogen-responsive cells in culture in the absence of steroid hormone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338970     DOI: 10.1007/bf02623814

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  26 in total

1.  Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF.

Authors:  F Esch; A Baird; N Ling; N Ueno; F Hill; L Denoroy; R Klepper; D Gospodarowicz; P Böhlen; R Guillemin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

2.  The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor.

Authors:  J Massagué; M P Czech
Journal:  J Biol Chem       Date:  1982-05-10       Impact factor: 5.157

3.  The growth of cells in serum-free hormone-supplemented media.

Authors:  J Bottenstein; I Hayashi; S Hutchings; H Masui; J Mather; D B McClure; S Ohasa; A Rizzino; G Sato; G Serrero; R Wolfe; R Wu
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

4.  Autocrine secretion and malignant transformation of cells.

Authors:  M B Sporn; G J Todaro
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

5.  Identification of estrogen-inducible growth factors (estromedins) for rat and human mammary tumor cells in culture.

Authors:  T Ikeda; Q F Liu; D Danielpour; J B Officer; M Iio; F E Leland; D A Sirbasku
Journal:  In Vitro       Date:  1982-12

6.  Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells.

Authors:  R B Dickson; K K Huff; E M Spencer; M E Lippman
Journal:  Endocrinology       Date:  1986-01       Impact factor: 4.736

7.  Purification and properties of a mammary-uterine-pituitary tumor cell growth factor from pregnant sheep uterus.

Authors:  T Ikeda; D A Sirbasku
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

8.  Phosphoethanolamine as a growth factor of a mammary carcinoma cell line of rat.

Authors:  T Kano-Sueoka; D M Cohen; Z Yamaizumi; S Nishimura; M Mori; H Fujiki
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

9.  Control of cell growth. II. Requirement of thyroid hormones for the in vivo estrogen-dependent growth of rat pituitary tumor cells.

Authors:  J M Sorrentino; W L Kirkland; D A Sirbasku
Journal:  J Natl Cancer Inst       Date:  1976-06       Impact factor: 13.506

10.  Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cells.

Authors:  I Perroteau; D Salomon; M DeBortoli; W Kidwell; P Hazarika; R Pardue; J Dedman; J Tam
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

View more
  6 in total

1.  Estrogen mitogenic action. III. is phenol red a "red herring"?

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

Review 2.  Serum-free culture of carcinoma cell lines.

Authors:  P Collodi; C Rawson; D Barnes
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

3.  A new serum-free method of measuring growth factor activities for human breast cancer cells in culture.

Authors:  M Ogasawara; D A Sirbasku
Journal:  In Vitro Cell Dev Biol       Date:  1988-09

4.  Insufficiency of transformation by simian virus 40, polyomavirus, EJ-ras, or v-myc oncogenes for conversion of ethanolamine-responsive mammary cells to ethanolamine-nonresponsive cells.

Authors:  T Kano-Sueoka; D M King
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

5.  Estrogen mitogenic action. I. Demonstration of estrogen-dependent MTW9/PL2 carcinogen-induced rat mammary tumor cell growth in serum-supplemented culture and technical implications.

Authors:  J E Moreno-Cuevas; D A Sirbasku
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

6.  Estrogen mitogenic action. ii. negative regulation of the steroid hormone-responsive growth of cell lines derived from human and rodent target tissue tumors and conceptual implications.

Authors:  D A Sirbasku; J E Moreno-Cuevas
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Jul-Aug       Impact factor: 2.416

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.